Money is flowing back into cannabis equities at a pace the sector hasn't seen in years. The AdvisorShares Pure US Cannabis ETF (MSOS) has climbed to its highest levels of 2026, with a 103.7% one-year net asset value return that dwarfs the North American Marijuana Index's 36.9% gain and the S&P 500's 29.8%. The catalyst isn't subtle: a DEA administrative hearing on marijuana rescheduling is set for June 29, and Trulieve's landmark listing on the NYSE has given investors a fresh reason to bet on the industry's path toward mainstream capital markets.
Trulieve's move to the senior exchange, trading under TRLV, matters beyond the ticker symbol. The company split its medical cannabis operations from its adult-use business specifically to clear listing requirements - a structural maneuver more multi-state operators will likely study closely. For operators managing sprawling retail footprints across medical and adult-use markets simultaneously, the operational complexity behind that kind of separation is real: distinct inventory tracking, separate compliance logs, and different tax treatment depending on jurisdiction. That's part of why platforms built for multi location dispensary software new mexico and similar fragmented regulatory markets have become essential rather than optional - seed-to-sale tracking and POS systems need to distinguish medical from adult-use transactions cleanly, especially as companies restructure to satisfy exchange rules or state licensing frameworks. multi location dispensary software new mexico
What The DEA Hearing Actually Decides
The June hearing will examine whether marijuana - not just state-licensed medical products - should move to Schedule III. That's a bigger question than it sounds. Back in April, Acting Attorney General Todd Blanche shifted state-licensed medical cannabis into Schedule III, which eliminated the harshest tax penalty operators have lived under for years: Section 280E, the tax code provision that barred cannabis companies from deducting ordinary business expenses like payroll and rent because the plant remained a Schedule I substance. Extending that relief to adult-use products would be a materially bigger deal for the balance sheets of companies like Curaleaf, Green Thumb, and Cresco Labs, all of which carry significant adult-use exposure.
In practice, though, hearings like this rarely resolve in a single sitting. The proceeding is expected to stretch through mid-July, and administrative processes of this kind can produce delays, appeals, or narrower rulings than markets initially price in. Investors piling into MSOS ahead of the date are, in effect, betting on regulatory momentum continuing in a straight line. It rarely does.
Financing And Uplisting: The Real Business Story
Beyond the ticker-watching, rescheduling carries concrete operational implications. Cresco Labs' newly secured $50 million revolving credit facility from Needham Bank is a preview of what looser tax treatment and clearer federal posture can unlock: non-dilutive financing that multi-state operators have struggled to access through traditional banking channels for over a decade. Cannabis remains a cash-intensive, compliance-heavy retail business - dispensaries still wrestle with cashless payment workarounds, inventory shrinkage controls, and the everyday cost of maintaining compliant packaging and lab-tested product batches. Better access to capital doesn't remove those burdens, but it does give operators more room to invest in the systems - POS terminals, wholesale menu management, compliance software - that keep them audit-ready.
Reading The Upside Numbers With Some Caution
Analyst price targets circulating among MSOS holdings show wide dispersion. Verano carries the steepest implied upside at 195%, with Jushi Holdings and Cresco Labs also showing triple-digit potential, according to Koyfin data cited by market analysts. Green Thumb Industries, at 70% upside, stands out among the larger holdings, ahead of both Trulieve and Curaleaf. Glass House is the outlier with a negative upside estimate, a reminder that not every name in the ETF is riding the same wave.
Retail sentiment on platforms like Stocktwits has turned "extremely bullish" for several of these tickers, with elevated message volume. That's worth noting as a signal of enthusiasm, not as a substitute for fundamentals. Price targets are estimates, not promises, and cannabis equities have a well-earned reputation for volatility tied to regulatory headlines rather than steady operating metrics. For operators, brands, and investors alike, the sharper lesson from this run-up may be less about which stock wins and more about how quickly compliance infrastructure, tax treatment, and capital access are converging to reshape the sector's economics.
